Loading...
•
Jun 30, 2022
Cerus Q2 2022 Earnings Report
Cerus's Q2 2022 results showed record product revenue and a 26% year-over-year increase in total revenue.
Key Takeaways
Cerus Corporation announced record product revenue for the second quarter of 2022, with total revenue reaching $47.6 million, a 26% increase year-over-year. The company reiterated its full-year 2022 product revenue guidance of $160-165 million.
Total revenue for Q2 2022 was $47.6 million, a 26% increase year-over-year.
Product revenue for Q2 2022 was $41.0 million, a 30% increase year-over-year.
Net loss attributable to Cerus Corporation for Q2 2022 was $8.4 million, or $0.05 per share.
The company reiterated its full-year 2022 product revenue guidance of $160-165 million.
Cerus
Cerus
Cerus Revenue by Segment
Cerus Revenue by Geographic Location
Revenue by Segment
Product Revenue
CapyFin.comGovernment Contract Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comEurope, Middle East and Africa Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
The Company expects full-year 2022 product revenue will be in the range of $160-165 million, representing strong growth of approximately 22%-26% compared to full-year 2021 product revenue of $130.9 million.
Positive Outlook
- Reiterating full-year 2022 product revenue guidance range of $160-165 million.
- Strong underlying demand for products.
- Growth opportunities expected to offset foreign exchange headwinds.
- Continued financial discipline.
- Well positioned and securely capitalized to achieve cashflow breakeven.
Challenges Ahead
- Significant macroeconomic issues challenging various aspects of the global economy.
- Expected persistence of foreign exchange headwinds.
- Uncertainty of future capital requirements.
- Risks associated with commercialization and market acceptance of the INTERCEPT Blood System.
- Risks related to adverse market and economic conditions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income